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Fulminant hepatic failure in pregnant women: acute fatty liver or 
acute viral hepatitis? 
Saeed S. Hamid, S. M Wasim Jafri, Haleem Khan, Hasnain Shah, Zaigham Abbas and Howard Fields 
Department of Medicine, The Aga Khan University Hospital, Karachi, Pakistan and Center for Disease Control, Atlanta, USA 
Background: Hepatitis E virus, which is endemic 
in our region, can cause severe liver dysfunction 
in pregnant women and this can be clinically con- 
fused with acute fatty liver of pregnancy. 
Methods: We studied the clinical and laboratory 
data as well as the maternal and fetal outcomes of 
12 pregnant women presenting with fulminant 
hepatic failure in order to determine the etiology 
of the disease. The clinical diagnoses were subse- 
quently correlated with serologic assays for acute 
HEV infection. All patients were severely ill with 
deep jaundice, grade 3-4 encephalopathy and 
abnormal prothrombin times. 
Results: A clinical diagnosis of acute viral hepati- 
tis was made in nine patients and of acute fatty 
liver in the other three cases. IgM and IgG anti- 
bodies confirmed acute viral hepatitis E in six of 
the nine patients while one had acute hepatitis A 
infection. HEV IgM and IgG antibodies were, 
however, also positive in two of the three patients 
thought to have acute fatty liver. Maternal and 
fetal mortality were 16.6% and 50%, respectively. 
Conclusions: We conclude that hepatitis E is the 
usual cause of acute liver failure in our pregnant 
women and that clinical and laboratory features 
do not permit accurate distinction between acute 
HEV infection and acute fatty liver of pregnancy. 
The prognosis in patients with acute HEV infec- 
tion is much better than in other groups with 
severe liver failure (mortality 16% vs 68%). 
Key words: Acute fatty liver; Fulminant hepatic 
failure; Hepatitis E; Pregnancy. 
S EVERE liver dysfunction in late pregnancy is an unusual but dramatic event because it can 
progress very rapidly to fulminating disease and also 
because two lives, that of the mother and fetus, are 
involved. The important causes of such an event are 
acute viral hepatitis, acute fatty liver of pregnancy, 
pre-eclampsia related liver disease, tetracycline 
induced liver damage and the "HELLP" (Hemolysis, 
Elevated Liver enzymes and Low Platelet count) syn- 
drome (1). Amongst these, acute viral hepatitis 
(AVH) and acute fatty liver of pregnancy (AFLP) are 
the commonest and can be clinically confused with 
each other. 
Acute hepatitis during pregnancy can occur with 
any of the hepatotropic viruses. However, with regard 
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to pregnancy, acute hepatitis E virus (HEV) infection 
is of most interest as it can assume a fulminating 
course in a high proportion of pregnant women (2,3). 
Pakistan is situated in a region where enterically 
transmitted non-A, non-B hepatitis, which includes 
hepatitis E, is endemic (4). However, due to the non- 
availability of a serological test for HEV, accurate 
epidemiological information regarding this virus is 
not available from our country. 
It is important o be able to differentiate between 
severe acute viral hepatitis and AFLP for three rea- 
sons: (a) The epidemiology of both diseases needs to 
be defined in pregnant women in our region, (b) 
Treatment options may be different, as prompt ermi- 
nation of pregnancy is usually required for improving 
prognosis in acute fatty liver (5), and (c) long-term 
prognosis may be different in both groups, with 
recent reports suggesting the AFLP can recur in sub- 
sequent pregnancies (6). However, there are limita- 
tions to accurate diagnosis of both conditions e.g. 
reliable and reproducible serological tests for the 
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diagnosis of acute HEV infection are not widely 
available and a liver biopsy, which is often essential 
for the accurate diagnosis of AFLP, is usually not 
possible because of the gross coagulation derange- 
ments in these patients. Physicians are therefore usu- 
ally left with formulating a diagnosis based on clini- 
cal and laboratory parameters. Although certain fea- 
tures are thought o be distinctive of either AVH or 
AFLP (6,7), there is overlap in a number of parame- 
ters, making a confident clinical diagnosis difficult in 
many instances. 
We report a descriptive study of pregnant women 
presenting with severe liver dysfunction. Our aims 
were: (1) to study the clinical, biochemical and sero- 
logical profile of these patients in order to determine 
the etiology of the disease; (2) to correlate our clini- 
cal diagnosis in these patients with the serological 
tests for HEV; and (3) to determine the maternal and 
fetal prognosis in these patients. 
Patients and Methods 
During a 3-year period from July 1991 to July 1994, 
the total number of deliveries at our hospital was 
5935. Of these, 52 patients 0.87% developed jaundice 
during pregnancy. Although complete data are not 
available in some cases, 30 of these 52 patients were 
considered to be suffering from acute viral hepatitis, 
the other diagnoses made being intra-hepatic 
cholestasis of pregnancy in ten, chronic viral hepatitis 
in three, HELLP syndrome in three, cholelithiasis in 
three, and other infections in three (Dr. Aliya, unpub- 
lished data). 
Twelve of these 5935 patients (0.2%) presented to 
hospital in fulminant hepatic failure (FHF), which is 
defined here as progression to hepatic encephalopa- 
thy within 15 days of the onset of jaundice in the 
absence of known previous liver disease (8). The 
encephalopathy was graded according to the standard 
classification from grade one to four (9). In only two 
patients was the pregnancy being supervised by med- 
ically trained persons while all others were being 
seen at home by dias (traditional birth attendants). All 
patients were managed in an intensive care unit set- 
ting and according to standard recommendations for
the conservative treatment of FHE Briefly, the treat- 
ment measures consisted of nursing patients at 20 ° 
head-up tilt, early use of mannitol provided renal 
function was normal, aggressive lactulose therapy, 
maintenance of blood sugar levels by 10% dextrose 
infusions, prophylactic antibiotics and mechanical 
ventilation in cases of respiratory distress. Liver tests 
including serum bilirubin, alanine aminotransferase 
(ALT), alkaline phosphatase, serum albumin and pro- 
FHF in pregnant women 
thrombin times were checked serially. Other bio- 
chemical aboratory data were recorded, including 
blood sugars, serum creatinine, electrolytes and 
serum uric acid. Hematology profile included white 
cell and platelet counts and tests for disseminated 
intravascular coagulation (DIC). If the FDP levels 
were greater than 20 ~tg/ml, APTT was 1.5 times the 
upper limits of normal and platelets were below 
150,000, DIC was diagnosed to be present. 
Hepatitis A IgM antibody, hepatitis B surface anti- 
gen and hepatitis C antibody (2nd generation ELISA) 
were assayed in all patients. In those who were HBsAg 
positive, hepatitis B core IgM and hepatitis delta anti- 
body (IgG and IgM) were also checked. All serologi- 
cal tests were done using ELISA assays from Abbott 
Diagnostics and read on a Quantum II analyzer. Sera 
stored at -70°C were available from eight patients for 
subsequent testing (not available for patients 4, 5, 11 
and 12). The stored sera were processed by PCR for 
detection of HCV RNA, according to the methodol- 
ogy described by Beach et al. (10), and were also sent 
to Centers for Disease Control Atlanta, USA, where 
the HEV antibodies (IgM and IgG) were tested 
according to the following methodology. 
HEV serology 
This was done with a newly developed EIA method 
(H. Fields, manuscript in preparation). The assay uti- 
lizes an artificial recombinant protein composed of 
multiple linear antigenic epitopes from ORF2 and 
ORF3 from both the Burma and Mexico strain of 
HEV on a single molecule. The assay format has 
been previously described (11). The EIA method 
used was shown to be essentially equivalent in sensi- 
tivity and specificity to a commercially available kit 
when used on epidemiologically well-characterized 
sera previously tested by Western blot (12). 
Results 
Demographic and clinical features 
Table 1 shows the demographic and clinical features 
of our patients. Mean age was 25 years and two- 
thirds of patients were multigravida. The majority 
had a low socioeconomic/educational background as 
assessed by the area of residence, the nature of the 
husband's job and basic education of the patient. All 
were urban residents from different parts of the city. 
Only two were being followed up in hospital for their 
pregnancies. Apart from patients 1 and 2, all pre- 
sented uring the third trimester around a mean of 32 
weeks. Progression to encephalopathy from the onset 
of jaundice was rapid in most cases (1 week or less in 
9/12 patients) and all but one progressed tograde 3-4 
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TABLE 1 
Demographic and clinical features of pregnant women with FHF 











1 22 5 16 
2 21 3 19 
3 25 2 28 
4 35 3 28 
5 26 2 34 
6 26 2 32 
7 25 5 33 
8 30 2 35 
9 28 1 34 
10 22 1 34 
11 22 1 33 













encephalopathy. Vomiting was a common prodromal 
symptom but fever and abdominal pain occurred 
infrequently. There were no clinical features to sug- 
gest the presence of pre-eclampsia in any patient such 
as proteinuria, hypertension or edema. There was no 
history of jaundice in previous pregnancies in the 
multi-gravid patients. There was no significant his- 
tory of recent drug intake in any patient. 
Laboratory features 
Table 2 shows the relevant laboratory features. All 
patients were severely jaundiced at presentation 
(mean bilirubin of 16.4 mg/dl). In almost all patients 
who survived, the total bilirubin values worsened 
before they began to fall. A wide range of serum ALT 
levels was observed, from 114 I.U. per liter in Patient 
10 to 4830 I.U. per liter in Patient 12. A significant 
element of cholestasis was present in most cases, as 
shown by a mean alkaline phosphatase value of 320 
IU/1, although it is possible that minor elevations of 
non-hepatic alkaline phosphatase may occur in nor- 
mal pregnancies. Prothrombin times were abnormal 
in all cases and in three were grossly abnormal at 
greater than 120 s. Serum albumin levels were below 
normal in all except one and were markedly low (less 
than 2 g/dl) in three patients. On a peripheral blood 
film burr cells, along with fragmented red cells and 
polychromasia, were seen in five patients. Patient No. 
6 had occasional target cells but no normoblasts or 
giant platelets. Blood sugars were low (less than 80 
TABLE 2 
Laboratory features of pregnant women with FHF 
Pt. Serum bilirubin Max. ALT Max.serum Peak prothrombin 
no at presentation (n=0-55 iu/l) alkaline time 
(n=0.2-1.25 phosphatase (control 11-13 s) 
mg/dl) (n=28-124 iu/1) 
Serum Min. blood Serum uric White cell count 
albumin sugar acid (at presentation) 
(n=3.2-5 g/dl) (mg/dl) (n--4.1-8 
mg/dl) 
1 12.9/3.1" 683 145 25 
2 11.7/4.1 1150 166 25 
3 19.7/8.4 258 230 >120 
4 14.5/7 1053 350 52 
5 6/2.9 2167 280 >120 
6 29.6/18 714 459 21 
7 22/7.5 760 450 24 
8 18.7/10 1588 375 34 
9 17.4/6.1 118 320 33 
10 20/12.5 114 110 >120 
11 15.1/5.2 262 643 57 
12 9.9/2.0 4830 315 36 
2.1 33 -**  15.8 
2.4 156 0.8 10.3 
2.2 46 - 15.0 
3.0 71 - 15.4 
3.5 56 0.4 13.9 
1.8 59 - 10.3 
2.1 61 - 17.7 
2.2 48 - 15.7 
1.7 11 2.6 23.2 
1.8 31 4.9 29.1 
2.5 97 5.6 20.6 
2.5 59 - 12.4 
* Figures show total and direct bilirubin. 
** (-) indicates not tested. 
22 
Fig. 1. High power view showing diffuse infiltration with 
chronic inflammatory cells, ballooning of hepatocytes, mi- 
crovesicular fatty change (moderate degree) and arrange- 
ment of hepatocytes inan acinar pattern. 
mg/dl) in all except wo. Serum uric acid was meas- 
ured in all the three patients diagnosed clinically to 
have AFLP (patient 9, 10 and 11) and was found to 
be normal or just below normal. However serum uric 
acid was interestingly markedly low (less than 1 mg/ 
dl) in the two patients with AVH in whom it was 
measured. White cell counts were elevated (greater 
than 109]1) in ten patients and grossly elevated 
(greater than 209/1) in the three patients thought o 
have AFLE Microbiologically confirmed infections 
were, however, found in only three patients (No. 3, 
10 and 12) and these were urinary tract infections 
with E. coli in two and pneumonia with Strep. pneu- 
moniae in the third patient. An ultrasound scan was 
done in all patients but did not show any evidence of 
obstruction or the presence of excess fat in any case. 
ACT scan of liver was subsequently done in the two 
patients clinically diagnosed to have AFLP (patients 
9 and 10) and in both cases showed normal liver 
attenuation. 
FHF in pregnant women 
Hepatitis erology 
Patient 12 was HAV IgM antibody positive, thus con- 
firming acute hepatitis A infection (Table 3). All oth- 
ers were negative for HAV IgM and HCV antibodies. 
Patients 1 and 2 were positive for HBsAg but were 
negative for HBc IgM and HDV antibodies, suggest- 
ing that they were carriers of HBV and not cases of 
acute hepatitis B. All the eight available sera were 
negative for HCV RNA on PCR, thus excluding the 
possibility of acute HCV infection. All these eight 
sera were positive for HEV antibody IgM, confirming 
acute hepatitis E infection in these cases. All but one 
(patient 7) were also positive for HEV IgG antibody. 
Of the three patients diagnosed as having AFLP (No. 
9, 10 and 11 ), two had sera available for further anal- 
ysis (No. 9 and 10), and both were HEV antibody 
IgM and IgG reactive. 
Liver histology 
Only one patient (No. 5) gave consent for a liver 
biopsy. This was done during the same admission, as 
soon as the platelets and coagulation profile normal- 
ized. The liver architecture was preserved. There was 
diffuse infiltration with mainly chronic inflammatory 
cells but also some neutrophils, associated with bal- 
looning and arrangement of hepatocytes in an acinar 
pattern (Fig. 1 and 2). This appearance has been fre- 
quently observed in cases of acute HEV infection (13). 
There was a moderate degree of microvesicular fatty 
change. 
Complications 
Five patients (No. 5, 7, 9, 10 and 11) developed renal 
impairment, as evidenced by a raised serum creati- 
Fig. 2. Low power view shows intact liver architecture 
with diffuse inflammatory cell infiltrate in the lobules. Bal- 
looning of hepatocytes with microvesicular fatty change 
and acinar formation is evident. 
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TABLE 3 
Hepatitis erology profiles of pregnant women with FHF 
Pt. no. HAV IgM HBsAg HBc IgM HDV HCV PCR for Anti-HEV antibody 
antibody antibody HCV RNA 
IgM 
1 N. R* Reactive N.R. N.R. N.R. Negative Reactive 
2 N.R. Reactive N.R. N.R. N.R. Negative Reactive 
3 N.R. N.R. -** - N.R. Negative Reactive 
4 N.R. N.R. - - N.R. - - 
5 N.R. N.R. - - N.R. - - 
6 N.R. N.R. - - N.R. Negative Reactive 
7 N.R. N.R. - - N.R. Negative Reactive 
8 N.R. N.R. - - N.R. Negative Reactive 
9 N.R. N.R. - - N.R. Negative Reactive 
10 N.R. N.R. - - N.R. Negative Reactive 
11 N.R. N.R. - - N.R. - - 










* N.R. indicates not reactive. 
** (-) indicates not tested. 
TABLE 4 
Maternal and fetal outcomes in pregnant women with FHF 
Pt. no. Maternal Fetal outcome Pregnancy Sex of fetus Length of 
outcome outcome hospital 
stay (days) 
1 Alive Live birth Full-term -* 6 
2 Alive Live birth Full-term - 6 
3 Alive Died after 2 days S.V.D ** - 24 
day -2*** 
4 Alive Still birth Induced - 13 
day 0 
5 Alive Live birth S.V.D. - 20 
day +3 
6 Alive Live birth S.V.D. Male 7 
day + 1 
7 Alive Still birth S.V.D. Male 10 
day -1 
8 Alive Live birth Induced - 7 
day + 1 
9 Alive Died same day S.V.D. - 17 
day -1 
10 Died Still birth S.V.D. Male 9 
day -1 
11 Died Died Induced Male 5 
day -1 
12 Alive Live birth S.V.D. Male 
day -3 8 
*(-) indicates not known. 
** S.V.D. = Spontaneous vaginal delivery. 
*** Day 0 = Day of admission to our hospital. 
nine (range 1.8 to 7.1 mg/dl, normal up to 1.2 mg/dl), 
but none required or were considered suitable for 
dialysis (patient 11). Evidence of DIC was present in 
seven patients and of these, six had significant post 
partum hemorrhage (PPH) requiring blood transfu- 
sions. Two of these patients also had upper G.I. 
bleeding. Four patients required mechanical ventila- 
tion for respiratory distress including the two patients 
who died. 
Maternal and fetal outcome 
Patients 10 and 11 died, giving a mortality rate of 
16.6%. The ten surviving patients have completely 
normal biochemical liver tests at follow up. One of 
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these (patient No. 5) developed transient neuro-psy- 
chiatric symptoms. She had required an extended 
period of mechanical ventilation. One of the surviv- 
ing patients has recently completed an uncomplicated 
full-term pregnancy, and another one is currently 
pregnant without any complications. The average 
length of hospital stay of approximately 12 days sug- 
gests that most patients got better quickly once they 
started to recover. Fetal mortality, however, was high 
at 50% with three still births and three deaths within 
2 days of delivery. All deliveries occurred spontane- 
ously, except wo where induction with Prostagland- 
ins or Syntocinon infusion was required. As can be 
seen in Table 4, the timing or mode of delivery did 
not seem to influence maternal outcome in this small 
group of patients. 
Clinical diagnosis 
On admission, patients 9, 10 and 11 were diagnosed 
as having AFLP by the attending physicians. This 
was because they were all primigravida in the third 
trimester of pregnancy, the ALT levels were only 
moderately elevated (less than 300 IU/I) with signifi- 
cant cholestasis, there was evidence of DIC, all had 
marked leucocytosis in the absence of documented 
infection, and all developed renal failure. All these 
features are considered to be highly suggestive of 
AFLP (1,5,6,7,14), although none are pathogno- 
monic. However, in two of these patients (No. 9 and 
10) the HEV antibody IgG and IgM was reactive, 
confirming the diagnosis of acute HEV infection. 
The other nine patients were diagnosed as having 
acute viral hepatitis. Six of these were serologically 
confirmed to have acute HEV, while one had acute 
HAV infection. Although patient No. 3 did not have a 
marked elevation of ALT, other features uggestive of 
AFLP were missing. 
Discussion 
This study deals with acute sporadic HEV infection 
in pregnant women, causing FHE and it highlights 
the challenges faced by the clinician in dealing with 
such patients, particularly in the setting of a develop- 
ing country. The first challenge usually is to deter- 
mine the etiology of the disease because subsequent 
management decisions may depend on this. The two 
diseases that can be confused with each other in this 
setting are acute viral hepatitis and acute fatty liver of 
pregnancy. The problem becomes even more relevant 
in areas where the different hepatitis viruses are 
endemic. Hepatitis E, in particular, causes fulminant 
cholestatic hepatitis in a high proportion of pregnant 
women (3). 
FHF in pregnant women 
In the majority of our cases the clinical diagnosis 
of acute viral hepatitis was correct and was subse- 
quently confirmed by serological tests. However, our 
study suggests that in a number of instances, it may 
not be possible to distinguish clearly between AVH 
and AFLR A number of well-defined clinical, labora- 
tory and histological features have been described for 
AFLP (1,5,6,7,14), but none are considered pathog- 
nomonic. Based on these criteria, three of our cases 
were diagnosed to be suffering from AFLP, but sub- 
sequent serologic testing proved a viral etiology in at 
least two of them. Hence some cases of acute HEV 
infection will be confused with AFLE and vice versa. 
In the recent description of AFLP by Reyes et al. (6), 
a number of cases demonstrated a clinical and labora- 
tory profile very similar to that of our patients with 
acute HEV infection and could easily have been diag- 
nosed as having AVH if liver biopsies had not been 
available to support a diagnosis of AFLR 
Apart from an invasive procedure like a liver 
biopsy, some non-invasive investigations might point 
more towards AFLP than AVH if they are abnormal. 
For example, a significantly elevated serum uric acid 
level, usually associated with signs of pre-eclampsia, 
has been found in most patients with AFLP (5,7). 
Also the demonstration f excess fat in the liver on a 
CT or MRI scan may be a valuable technique to 
establish the diagnosis of AFLP (15). A CT scan in 
two of our patients thought o have AFLP was nega- 
tive for excess fat and could have helped in excluding 
this diagnosis. Our study supports a negative predic- 
tive value for CT liver in diagnosing AFLR 
Another approach would be the rapid diagnosis of 
acute viral hepatitis by employing a full battery of 
serologic tests. In Western countries, where HEV is 
rare, serologic tests for hepatitis A and B are readily 
available and should help clinicians to make a diag- 
nosis relatively quickly. However, accurate and relia- 
ble serologic tests for HEV are not widely available. 
In particular, tests to detect IgM antibody to HEV 
remain largely research-based. IgG antibody tests are 
commercially available but will not distinguish 
between acute and past infection in areas endemic for 
HEV. PCR-based methods to detect HEV antigen in 
stool and serum have been described (16), but again 
these remain largely experimental nd unrealistic due 
to excessive cost. 
The second interesting point we noted in our study 
is the remarkably good prognosis of these seriously 
ill women on conservative treatment alone. Even 
though the disease became so severe, the maternal 
mortality was only 16%. This clearly becomes mean- 
ingful when we compare it to mortality in our other 
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groups with FHE For example, during the same study 
period we admitted 26 other patients with FHF (20 
males and six non-pregnant females) and the mortal- 
ity in this group was 68% (70% in males and 66% in 
non-pregnant women) (17). This substantial differ- 
ence cannot be explained on any variations in treat- 
ment, as this was more or less according to a standard 
protocol, but could be explained on the differences in
etiology because most patients who died had acute 
hepatitis B infection. Thus, although the disease may 
progress dramatically in pregnant women, the overall 
prognosis is better than for other FHF groups and the 
usual indicators of poor prognosis described in the 
literature may not hold true in these patients. 
For example, if the criteria proposed by O'Grady 
et al. (18) for liver transplantation i  FHF due to 
causes other than paracetamol poisoning were used, 
five patients would have been eligible for transplanta- 
tion. This included the two patients who died (No.10 
and 11) but also three other patients (No. 3, 4 and 5) 
who survived. Patients 3, 5 and 10 would have been 
eligible for transplantation on the basis of a pro- 
thrombin time greater than 100 s. Patients 4 and 11 
fulfilled at least three criteria for transplant, namely a 
non-A, non-B etiology, prothrombin time greater than 
50 s and serum bilirubin greater than 300 gmol/1. Our 
mortality is also low when compared to other eports 
of acute HEV infection in pregnant women (2,3). 
However most of these studies deal with FHF in 
pregnant women during epidemics of HEV infection, 
whereas we report the outcome of sporadic HEV 
infection during pregnancy. The explanation for this 
difference is not clear but may have to do with differ- 
ences in viral load, with possibly higher viral load 
being present in patients infected uring epidemics of 
HEV. 
Why acute HEV infection in pregnant women 
causes severe liver dysfunction is not known. Poor 
nutritional status in these patients is often suggested 
as one of the major contributory factors, although no 
scientific proof is available. A lowered nutritional 
status lowers immune function, which may already 
be lowered in pregnancy (19). It is suggested that the 
increase in severity of viral hepatitis during preg- 
nancy may be dependent on the geographical location 
of the patient in an underdeveloped area (20), as a 
higher susceptibility to fulminant hepatitis has not 
been noted in pregnant women in the developed 
world (21). A possibly poor nutritional status is sug- 
gested in our patients by the quite low serum albumin 
values observed. 
Viral factors are also likely to be major determi- 
nants of disease severity. In pregnancy, especially late 
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pregnancy, viruses are more likely to spread rapidly, 
attain high titers in tissues and produce more severe 
disease. For example, a study of Lassa fever in preg- 
nant women found extremely high titers of the virus 
in placental tissue, suggesting that the placenta may 
be a preferred site of viral replication (22). It may be 
that such a situation also exists in HEV infection dur- 
ing pregnancy. If this was shown to be the case, early 
delivery in women with hepatitis E would be indi- 
cated. Studies which precisely measure risk factors 
for the severity of HEV in pregnancy are clearly 
required. 
In conclusion, in the regional setting our main aim 
in pregnant women with FHF should be the accurate 
and rapid diagnosis of acute HEV infection. AFLP in 
any case is thought o be a rare cause of severe liver 
dysfunction (23) and, in the final analysis, none of 
our patients probably had AFLR Therefore in coun- 
tries like Pakistan and other parts of the world where 
HEV is endemic, the availability of reliable serologi- 
cal tests for this virus would be of great help to clini- 
cians. We recommend that pregnant women with sus- 
pected viral hepatitis be admitted to hospital immedi- 
ately as a number of them may progress to FHE 
Although these patients rapidly develop fulminating 
disease, the overall prognosis is encouraging. Meticu- 
lous intensive care is likely to be very rewarding and 
hence a challenge for the clinician. However, a sepa- 
rate set of indicators of poor prognosis in this group 
of patients needs to be determined in order to define 
the role of therapies like liver transplantation. There 
are currently no data to support early delivery in 
severe HEV infection, but this needs evaluation in 
future studies. 
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